Rifaximin significantly improves bloating in IBS-D

In a composite of three trials, rifaximin provided a durable and significant improvement in bloating in patients with diarrhea-predominant irritable bowel syndrome as compared with placebo, according to results presented at UEG Week.“A significantly greater percentage of patients receiving rifaximin were durable bloating responders compared to placebo using again the greater than or equal to one-point or the greater than or equal to two-point responder definition,” Brian E. Lacy, MD, PhD, from the Mayo Clinic in Jacksonville, Florida, said during his presentation.Lacy andRead More

Share on facebook
Share on twitter
Share on linkedin